Article in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Adrien LupieriDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-9245-0169
Dakota Becker-GreeneDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-0344-8591
Thanh-Dat LeDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Marina M RoschelDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Prabhash K JhaDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abhijeet R SonawaneDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-1166-6479
Shiori KuraokaDivision of Cardiovascular Medicine, Center for Interdisciplinary Cardiovascular Sciences (A.R.S., S.K., S.A.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sasha A SinghDivision of Cardiovascular Medicine, Center for Interdisciplinary Cardiovascular Sciences (A.R.S., S.K., S.A.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-0929-3164
Masanori AikawaDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-9275-2079
Elena AikawaDivision of Cardiovascular Medicine, Center for Excellence in Vascular Biology (A.L., D.B.-G., T.-D.L., M.M.R., P.K.J., A.R.S., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-7835-2135
Funding
Improving Mitral Compensation In Ischemic RegurgitationR01HL141917 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AIKAWA, ELENA, BISCHOFF, JOYCE E. · 2018 to 2021
$5.6M
Macrophage-derived microcalcificaitonsR01HL136431 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2017 to 2020
$2.7M
New driver of fibrosis and calcification in CAVDR01HL147095 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2019 to 2022
backgroundAtherosclerotic calcification is a complex pathological process associated with an increased risk of cardiovascular events. Despite extensive research, this disorder has no effective therapeutic strategies. In this study, we evaluated the therapeutic potential of silencing Sort (sortilin) expression in vivo using antisense oligonucleotide (ASO-Sort1) to reduce the development of atherosclerosis and associated calcification.
methodsMale and female
resultsASO targeted primarily arterial smooth muscle cells, leading to a comparable reduction of aortic Sort1 expression by ≈57% in males and 52% in females. Although ASO-Sort1 did not affect the size of atherosclerotic lesions, it significantly reduced necrotic core development by 60% in male and 40% in female mice. In addition, it prevented aortic calcification by >50% only in male mice. Furthermore, proteome analysis revealed that while this treatment reduced vesicular trafficking, immune system, and extracellular matrix organization pathways in both male and female mice, it reduced autophagy-related processes specifically in males. In vitro results indicated that β-estradiol promotes calcification in smooth muscle cells treated with ASO-Sort1 by altering autophagy.
conclusionsTargeting Sort using antisense technology is effective in preventing vascular calcification in male mice. This unexpected outcome highlighted a novel sex-dependent discrepancy of the calcification pathway implicating the alteration of autophagy by β-estradiol and Sort.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Antisense Oligonucleotide Targeting Sortilin Reduces Vascular Calcification in Mice in a Sex-Dependent Manner. · full record | OpenQuestion